论文部分内容阅读
新血管生成是各种生理和病理过程发生的基础。在胚胎形成和胎盘发育等正常生理过程中,新血管的生成是至关重要的;然而对于一些疾病的产生,特别是肿瘤的生长、进展和转移,同样离不开血管生成的作用。伴随着“抗肿瘤血管生成疗法”的提出,控制血管生成“开关”的血管生成刺激因子和抑制因子成为研究的热点。Arresten、Canstatin、Tumstatin和Hexastatin是近些年发现的内源性的血管生成抑制因子,它们同系Ⅳ型胶原α链的非胶原区NC1,具有相似的结构和分子量大小,现有研究表明,它们能与内皮细胞表面整合素受体相结合,有效地抑制内皮细胞的增殖和迁移,降低肿瘤组织的微血管密度,切断肿瘤的营养和氧气供给,从而抑制肿瘤的生长和转移。对其作用机制的研究,将有助于肿瘤血管生成抑制剂新药的研发。
Neovascularization is the basis for various physiological and pathological processes. In normal physiology, such as embryogenesis and placental development, neovascularization is crucial; however, the generation of some diseases, especially tumor growth, progression and metastasis, is also inseparable from angiogenesis. With the proposed “anti-angiogenesis therapy”, angiogenesis stimulating factors and inhibitors that control angiogenesis “switch” become hot spots. Arresten, Canstatin, Tumstatin and Hexastatin are endogenous angiogenesis inhibitors found in recent years. They are similar in structure and molecular size to the non-collagenous region NC1 of collagen type IV collagen. Previous studies have shown that they can It binds to integrin receptors on the surface of endothelial cells and effectively inhibits the proliferation and migration of endothelial cells, reduces the microvessel density of tumor tissue, and cuts off the nutrition and oxygen supply of the tumor, thereby inhibiting tumor growth and metastasis. Research on its mechanism of action will help the development of new drugs for tumor angiogenesis inhibitors.